ALL INDIA DRUG ACTION NETWORK

Expert panel to soon weigh plan to use generics for prescription drugs

The proposal has become a bone of contention between the Indian Pharmaceutical Alliance (IPA), which represents the country's big drug makers, and the All India Drug Action Network (AIDAN), a network of several health organisations. The IPA is opposing the proposal to allow government-run Jan Aushadhi Kendras to dispense substitutes of prescription medications, claiming that it would open floodgates of similar demands by trade channels, such as general pharmacy stores, "which will not be in the interest of patients".

More in ALL INDIA DRUG ACTION NETWORK

Transfer of NPPA head who capped stent, implant prices sparks protests

RSS-affiliate Swadeshi Jagran Manch too has taken exception to the move, tweeting sarcastically about the “reward” given to a bureaucrat for doing a good job.
US stents dip in distribution in India after price caps

At the same time, Indian firms upped their share of the market to 61% in 2017 from 57% in 2016 after marginally increasing their distribution to 5.4 lakh from 5.1 lakh during the same period.
Angioplasty cost falls up to 18% on stent price cap

Angioplasty cost at corporate hospital chains came down by 8-12% to ₹2.05 lakh-2.20 lakh from ₹2.10 lakh-2.20 lakh, the study showed.
SC asks government to review its market-based drug pricing policy within six months

The Supreme Court on Wednesday asked the Central government to review its market-based drug pricing policy within six months.
Unauthorized buyers log into India to get drugs without prescriptions

A prescription for disaster is being written on the internet, in India, as unauthorized buyers log on to get drugs including stimulants and anti-depressants that should be sold only with a physician's recommendation.